



Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Sydney Dubois, Pierre-Julien Vially, Sylvain Mareschal, Elodie Bohers, Philippe Bertrand, Philippe Ruminy, Catherine Maingonnat, Jean-Philippe Jais, Pauline Peyrouze, Martin Figeac, et al.

► To cite this version:

Sydney Dubois, Pierre-Julien Vially, Sylvain Mareschal, Elodie Bohers, Philippe Bertrand, et al.. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. *Clinical Cancer Research*, 2016, 22 (12), pp.2919–2928. 10.1158/1078-0432.CCR-15-2305 . hal-01343064

HAL Id: hal-01343064

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01343064>

Submitted on 15 Dec 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Sydney Dubois¹, Pierre-Julien Vially^{1,2}, Sylvain Mareschal¹, Elodie Bohers¹, Philippe Bertrand¹, Philippe Ruminy¹, Catherine Maingonnat¹, Jean-Philippe Jais³, Pauline Peyrouze⁴, Martin Figeac⁴, Thierry J Molina⁵, Fabienne Desmots⁶, Thierry Fest⁶, Corinne Haioun⁷, Thierry Lamy⁶, Christiane Copie-Bergman⁸, Josette Brière^{9,10}, Tony Petrella¹¹, Danielle Canioni¹², Bettina Fabiani¹³, Bertrand Coiffier¹⁴, Richard Delarue¹⁵, Frédéric Peyrade¹⁶, André Bosly¹⁷, Marc André¹⁷, Nicolas Ketterer¹⁸, Gilles Salles¹⁴, Hervé Tilly¹, Karen Leroy¹⁹, Fabrice Jardin¹

1 Inserm U918, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France

2 LITIS EA 4108, Normandie Université, Rouen, France

3 Inserm UMRS 872, AP-HP Hôpital Necker, Paris, France

4 Université de Lille 2, Lille, France

5 Pathology, AP-HP, Hôpital Necker, EA 7324, Université Paris Descartes, France

6 Inserm U917, CHU Pontchaillou, Rennes, France

7 Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France

8 IMRB – Inserm U955, AP-HP Hôpital Henri Mondor, Créteil, France

9 Inserm U728, Université Paris Diderot, Sorbonne Paris Cité

10 Department of Pathology, AP-HP Hôpital Saint-Louis, Paris, France

11 Department of Pathology, Hôpital Maisonneuve-Rosemont, Montréal (QC), H1T2M4, Canada

12 Laboratoire de Pathologie, AP-HP Hôpital Necker, Paris, France

13 Laboratoire de Pathologie, AP-HP Hôpital Saint Antoine, Paris, France

14 CNRS UMR5239, Hospices Civils de Lyon, Lyon, France

15 Department of Hematology, AP-HP Hôpital Necker, Paris, France

16 Department of Hematology, Lacassagne Center, Nice, France

17 CHU Dinant Godinne, UCL Namur, Yvoir, Belgium

18 Department of Oncology, Lausanne Hospital, Lausanne, Switzerland

19 Inserm U955 Team 09, AP-HP Hôpital Henri Mondor, Créteil, France

Running Title: Targeted NGS details DLBCL divergence and actionable targets

Corresponding author: Fabrice Jardin

Address: 1 rue d'Amiens, Centre Henri Becquerel, Rouen, France

Email: fabrice.jardin@chb.unicancer.fr

Phone: +33 (0)232082465

Fax: +33 (0)232082455

Keywords: Diffuse Large B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, Next Generation Sequencing

Declaration of Interests: The authors disclose no potential conflicts of interest.

Total word count: 3866, Abstract word count: 247, Number of figures and tables: 6

Translational Relevance

This is the first Next Generation Sequencing (NGS) study of such a large, prospective cohort using a targeted gene panel, the Lymphopanel, focusing on genes identified as important for lymphomagenesis or whose potential has been pinpointed in Whole Exome Sequencing studies. Particular attention has been paid to the inclusion of actionable targets in the Lymphopanel, highlighting potential candidate patients for novel personalized therapies. This study further details subtype-enriched gene and pathway mutations in order to optimize DLBCL treatment, and highlights several novel, frequent, and actionable mutations, notably in PMBL. In addition, Lymphopanel NGS has enabled the detection of novel clinical and prognostic correlations, potentially impacting treatment decisions. As benchtop sequencers become increasingly available in academic research and routine clinical settings, our study demonstrates the feasibility and impact of NGS with a consensus gene panel in DLBCL patient management, contributing essential information to today's precision therapy era treatment decisions.

Abstract

Purpose: Next Generation Sequencing (NGS) has detailed the genomic characterization of Diffuse Large B Cell Lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose mutations hold potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value of these mutations in prospective clinical trials.

Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, selected according to literature data and a whole exome sequencing study of relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20+ *de novo* DLBCL in the prospective, multicenter and randomized LNH-03B LYSA clinical trials was sequenced to deep, uniform coverage with the Lymphopanel. Cell of origin molecular classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix GeneChip arrays.

Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that Activated B Cell-like (ABC), Germinal Center B-cell like (GCB) and Primary Mediastinal B-cell Lymphoma (PMBL) are frequently affected by mutations in NFkB, epigenetic, and JAK-STAT pathways respectively. Novel truncating immunity pathway, *ITPKB*, *MFHAS1* and *XPO1* mutations were identified as highly enriched in PMBL. Notably, *TNFAIP3* and *GNAI3* mutations in ABC patients treated with R-CHOP were associated with significantly less favorable prognoses.

Conclusions: This study demonstrates the contribution of NGS with a consensus gene panel to personalized therapy in DLBCL, highlighting subtypes' molecular heterogeneity and identifying somatic mutations with therapeutic and prognostic impact.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common form of adult lymphoma worldwide, accounting for 30-40% of newly diagnosed Non-Hodgkin Lymphoma (NHL)(1). Gene expression profiling (GEP) has made strides in deciphering the molecular heterogeneity of DLBCL, enabling the entity's subdivision into three main molecular subtypes: Germinal Center B-cell like (GCB), Activated B-Cell like (ABC), and Primary Mediastinal B-cell Lymphoma (PMBL)(2,3). Among other genetic aberrations, the GCB subtype is characterized by t(14;18)(q32;q21) translocations(4) and loss of *PTEN*(5), while the ABC subtype is characterized by t(3;14)(q27;q32) translocations, deletion of the *INK4A-ARF* locus(6) and *BCL2* amplification(7). PMBL displays strong molecular similarities to classical Hodgkin Lymphoma (cHL), exhibiting frequent amplifications of *JAK2* and deletions of *SOCS1*(8,9). Arising from B cells at distinct stages of differentiation and maturation, these subtypes are also diverse in clinical presentation, response to immunochemotherapy and outcome, with the ABC subtype having the most unfavorable prognosis(2,7). As targeted therapies become increasingly widespread, it is essential to thoroughly characterize each molecular subtype, in order to ensure optimal care for each patient. Unfortunately, the cell of origin (COO) classification of DLBCL still has relatively little influence on clinical practice, as GEP is poorly transposable to routine diagnosis and surrogate immunohistochemical algorithms remain unreliable(10), although recent techniques offer better bench to bedside translation(11,12).

Next generation sequencing (NGS) technologies, enabling high-throughput DNA sequencing, have emerged over the past decade and have provided new insights into the genomic characterization of DLBCL by identifying recurrent single nucleotide variants (SNVs), which can be enriched in a particular subtype(13–22). Although DLBCL is defined by widespread genetic heterogeneity, several of the pinpointed recurrent SNVs warrant special interest as they occur in actionable targets and/or correlate with antitumoral response. Equally of note, despite their probable physiopathological relevance, neither the prognostic value of these mutations nor their potential to predict resistance to conventional B-cell lymphoma immunochemotherapy treatment has been properly evaluated in prospective clinical trials. Furthermore, mutation feature analyses have identified activation-induced cytidine deaminase (AID)-driven somatic hypermutation (SHM) as a mechanism mediating the development of

some of these recurrent SNVs, rendering the task of distinguishing driver from passenger mutations even more challenging(23).

To more feasibly identify molecular subtypes and reach the goal of precision therapy in DLBCL, a limited and clinically relevant panel of target genes must be designed, with efforts made to thoroughly describe the SNVs they harbor. Furthermore, compact sequencers readily available in academic laboratories must be used in order to generalize this practice and apply it to routine clinical disease management. With this idea in mind, we developed a Lymphopanel NGS assay, designed to identify mutations in 34 genes important for lymphomagenesis based on a literature review of WES studies in DLBCL(13,14,20,24) as well as a WES study of relapsed/refractory DLBCL cases(25). In the current study, we sequenced 215 patients with *de novo* DLBCL enrolled in the prospective, multicenter and randomized LYSA LNH-03B trials, using the Lymphopanel. Our intent was to determine whether the Lymphopanel was informative enough to identify targetable SNVs and/or pathway mutations that might alter treatment decisions, highlight subtype-specific mutational profiles, distinguish genes impacted by AID, and potentially foretell clinical outcome.

Materials and Methods

Patients

215 adult patients with *de novo* CD20+ DLBCL enrolled in the prospective, multicenter and randomized LNH-03B LYSA trials with available frozen tumor samples, centralized histopathological review and adequate DNA/RNA quality were selected. The LNH03-B LYSA trials were initiated in 2003 and included 1704 patients overall in six distinct clinical trials (Supplementary Methods). COO molecular classification was obtained with HGU133+2.0 Affymetrix GeneChip arrays (Affymetrix), grouping patients into ABC, GCB, PMBL and “other”, also referred to as unclassified (detailed in Supplementary Methods). Clinical features of the patients are indicated in Table S1. The study was performed with approval of an institutional review board and written informed consent was obtained from all participants at the time of enrollment.

NGS experiments and data analysis

The Lymphopanel was designed to identify mutations in 34 genes important for lymphomagenesis, based on literature data (Table S2)(24) and WES of relapsed/refractory

DLBCL sequencing(25). The design covers 87 703 bases using 872 amplicons. Genes were grouped into 8 specific pathways: Immunity (*CIITA*, *B2M*, *TNFRSF14* and *CD58*), NOTCH (*NOTCH1* and *NOTCH2*), Apoptosis/Cell cycle (*MFHAS1*, *XPO1*, *MYC*, *CDKN2A/B*, *FOXO1*, *TP53*, *GNAI3* and *BCL2*), NFkB (*TNFAIP3*, *MYD88*, *PIM1*, *CARD11*, *IRF4* and *PRDM1*), Epigenetic Regulation (*EZH2*, *KMT2D*, *EP300*, *MEF2B* and *CREBBP*), MAP Kinase (*BRAF*), JAK-STAT (*SOCS1* and *STAT6*), and BCR (*CD79A/B*, *ITPKB*, *TCF3* and *ID3*) (Table S3).

Ion Torrent Personal Genome Machine (PGM) Sequencing and PGM data analysis was performed as previously described(26) and detailed in Supplementary Methods. Variant analysis was performed using an in-house generated bioinformatics pipeline, detailed in Supplementary Methods and Figures S1 and S2. This pipeline ensured excellent filtering of artefacts and polymorphisms, as proven by an independent study of seven non-tumoral samples from DLBCL patients with a mean error rate of non-filtered variants of only 0.7% (Table S4).

Statistical methods

All statistical analyses were performed using R software version 3.1.2(27). Progression-Free survival (PFS) was evaluated from the date of enrolment to the date of disease progression, relapse, re-treatment or death from any cause. Overall survival (OS) was evaluated from the date of enrolment to the date of death from any cause. Multivariate Cox and log-rank tests (“survival” R package version 2.37.7) were used to assess differences in OS and PFS rates calculated by Kaplan-Meier estimates. Ward hierarchical unsupervised clustering (“LPS” R package version 1.0.10) was performed using Jaccard distance. Statistical differences between all other parameters were determined using χ^2 , Mann-Whitney or Fisher’s exact tests when appropriate. P values or False Discovery Rates (FDR) < 0.05 were considered statistically significant.

Results and Discussion

Lymphopanel Variant Features

Lymphopanel NGS was performed on 215 DLBCL patients (81 ABC, 83 GCB, 33 “other” and 18 PMBL). The median overall sequencing depth was 225x [110x-331x]. An initial 13 965 variants were filtered for quality, SNPs and functional relevance, leading to 1064 (7.6%) variants ultimately validated (Table S5 and Figure S1). The Lymphopanel

informativity was of 96%, with 206 patients (78 GCB, 80 ABC, 30 “other” and 18 PMBL) presenting at least one variant. All genes in the Lymphopanel were informative for at least one patient, with the number of variants per gene ranging from one to 124. Gene mutation frequencies in the total cohort and by subtype are presented in Figure 1.

We subdivided the genes targeted by the Lymphopanel into eight specific pathways (Figure 2, Table S3). As expected, we confirmed that the ABC subtype is dominated by NFkB pathway mutations (45% of total variants), followed by epigenetic regulation pathway mutations (20.2% of total variants) (Figure 2A), whereas the GCB subtype is mostly characterized by mutations in the epigenetic regulation pathway (32.3% of total variants) and the apoptosis/cell cycle pathway (26.3% of total variants) (Figure 2B). Mutations in the JAK-STAT, immunity and apoptosis/cell cycle pathways were prevalent in PMBL (29.1%, 20.9% and 20.9% of total variants respectively) (Figure 2C). Interestingly, PMBL presented a significantly higher number of variants per sample than the other subtypes combined ($p=2.76 \times 10^{-5}$, Figure S3). The “other” subtype showed a fairly hybrid spectrum of pathway mutations (Figure 2D), perhaps suggesting the involvement of the three main subtypes, rather than the existence of a distinct entity.

We sought to assess the impact of AID involvement in the Lymphopanel genes (detailed in Supplementary Methods and Figure S4). Genes with an AID mutation frequency superior to the average of that of the Lymphopanel are presented in Table S6. Previously identified SHM targets in DLBCL among these genes include *MYC*, *PIM1*, *IRF4*, *BCL2*, *SOCS1* and *CIITA*(23). Potentially novel SHM targets include *MFHAS1*, *PRDM1*, *GNA13*, *MYD88*, *ITPKB* and *NOTCH2*. There was no significant difference in AID involvement between DLBCL subtypes.

Lymphopanel NGS identifies mutations with potential treatment impact

The Lymphopanel included genes whose mutations could serve to stratify patients according to treatment options. This includes actionable mutations, currently targeted by precision therapies, highlighted in Figure 1, as well as mutations whose presence might call into question the use of certain targeted therapy options.

Recent results have shown that doubly mutated *MYD88/CD79B* patients are significantly more responsive to single therapy Ibrutinib, a BTK inhibitor, highlighting the importance of targeted NGS for DLBCL patients in the clinical setting(28). Furthermore, the presence of *CARD11* and *TNFAIP3* mutations has been shown to lead to decreased activity of both Ibrutinib and Sotrastaurin, a Protein Kinase C inhibitor(29,30). *MYD88* mutations are frequent

in ABC DLBCL, L265P being the most prevalent variant (up to 29% in previous studies)(18). In our cohort, *MYD88* mutations were significantly enriched in ABC patients (28.4%, $FDR=4.7 \times 10^{-3}$), with the L265P mutation present in 21% of ABC patients (Figures 3 and S5A). Of 17 ABC patients with *MYD88* L265P mutations, we found ten (58.8%) with associated *CD79B* mutations, who might respond more favorably to Ibrutinib treatment. *CD79B* mutations were identified in 10.7% of total patients, slightly less than previously reported, but were significantly enriched in ABC DLBCL (24.7%, $FDR=3.2 \times 10^{-5}$), corroborating previous studies(13,31). Of note, two (11.8%) *MYD88* L265P mutated ABC patients were *CARD11* mutated and two were *TNFAIP3* mutated, potentially diminishing the effect of Ibrutinib and Sotrastaurin, while six (35.3%) were *PRDM1* mutated (Figure S6). ABC cells have been shown to be addicted to IRF4 activity (32), responsible for Lenalidomide treatment response. 21 *IRF4* variants were discovered in 7.9% of patients (13.6% of ABC, 4.8% of GCB, 0% of “other” and 11.1% of PMBL) (Figure 1). Although the impact on expression of these mutations was not analyzed, only one *IRF4* variant was a stop-gain mutation, indicating that expression is most likely at least conserved. Most of the non-synonymous SNVs were clustered around amino acid positions 18 (two S18 variants and two G20 variants) and 99 (four C99R variants, SIFT scores=0) (Figure 4). Interestingly, *IRF4* mutations were almost equally frequent in PMBL and ABC in our cohort. Although IRF4 addiction has not been demonstrated in PMBL, this predilection for *IRF4* mutations, added to the well-known high expression of IRF4 in this subtype, may suggest a potential role for Lenalidomide treatment in this subtype as well, calling for further investigation of these mutations’ effects. Recently, small molecule inhibitors of PIM kinases have been developed and studied in DLBCL. In our cohort, *PIM1* mutations were significantly skewed toward ABC (33.3%, $FDR=3.3 \times 10^{-5}$) in our cohort and represented 20.2% of ABC variants (Figures 2A, 3 and S5A). Of note, truncating *PIM1* variants were predominant in ABC patients (13 of 14 identified). Interestingly, DLBCL sensitivity to PIM kinase inhibitors is not correlated with the level of PIM kinase expression (33), suggesting that even expression-modifying *PIM1* mutations might not necessarily hamper the efficacy of PIM1 inhibitors, although this remains to be verified. In any case, the high frequency of *PIM1* mutations in our cohort seems to justify the pre-screening of PIM kinase inhibitor candidate patients by *PIM1* sequencing, in order to identify those most likely to benefit from this targeted therapy. The most highly mutated gene in GCB, *BCL2*(34), can notably be targeted by BH3-mimetics. Among our GCB cohort, *BCL2* was the third most frequently mutated gene (24.1%,

FDR=2.5x10⁻⁵) (Figures 3 and S5B), with mutations most frequently impacting the amino terminus and between the BH1 and BH3 domains. The BH3 domain was not impacted, indicating that BH3 mimetic activity would not be hampered in these patients (Figure S7). Targeting epigenetic changes is also being increasingly explored in the realm of tailored therapy, notably among the GCB subtype, justifying the inclusion of genes such as *EZH2*, *CREBBP*, *KMT2D* and *EP300* within the Lymphopanel. In our cohort, 18.1% of GCB patients were *EZH2* mutated, mostly at the Y641 hotspot, and *EZH2* mutations were enriched in GCB (FDR=1.8x10⁻³), as observed in previous studies, with no *EZH2* mutated ABC patients(13) (Figures 3 and S5B). Interestingly, one PMBL patient presented an *EZH2* Y641 mutation, adding to the debate of which DLBCL subtypes might benefit from *EZH2* inhibitor treatment(26). *CREBBP* mutations were identified in 31.3% of GCB patients and 6.2% of ABC patients, corroborating previous studies(17), but were also found in 24.2% of “other” and 11.1% of PMBL (Figures 1 and S5). *KMT2D* mutations, evenly distributed throughout the coding sequence, were identified in 40.9% of our cohort, with *KMT2D* being the most frequently mutated gene in all subtypes except PMBL (Figure 1). Of the 124 variants, 78 were truncating mutations, indicating bias toward loss of protein expression. Mutations of master regulators *TP53* and *MYC* showed no significant difference in subtype distribution in our cohort (Figure 3). *TP53* variants were present in 14.9% of total patients (slightly less than previously reported(13,35)) (Figure 1) and several recurrent variants were identified, including six R248 variants, shown to be loss of function mutants in DLBCL(35). As for *MYC*, we discovered mutations in 6.5% of total patients (4.9% of ABC, 9.6% of GCB, 3% of “other” and 5.6% of PMBL). No mutations were identified at the known hotspots in Burkitt Lymphoma (BL), including S62 and T58. Finally, although frequent mutations are most enticing for therapeutic potential, rare mutations can also be potentially very effectively actionable. For instance, *BRAF* and *NOTCH1* mutations have been identified as rare but functionally relevant in DLBCL(13). In our cohort, we identified one patient with an activating V600E *BRAF* variant. As for *NOTCH1*, ten patients in our cohort presented mutations (Figure 1). *TCF3* was mutated in three patients, all of whom harbored a pathogenic N551K variant, which has shown altered DNA-binding specificity(36). The negative regulator of *TCF3*, *ID3*, was mutated in 4.7% of patients (Figure 1), with most variants affecting the HLH domain (Figure S7), potentially impairing its ability to inactivate *TCF3*, as shown in BL(36). *ID3* and *TCF3* mutations have recently been shown to be of comparable frequency in BL and DLBCL, highlighting the overlap between these two entities(37).

The Lymphopanel highlights a unique PMBL mutational signature

STAT6 and *SOCS1* mutations were both very significantly enriched in PMBL (FDR=6.8x10⁻¹⁴ and FDR=2.5x10⁻⁵ respectively), with *STAT6* being the most frequently mutated gene in PMBL (72.2%, Figures 3 and S5C). All *STAT6* mutations were non-synonymous SNVs and recurrent variants were frequent among PMBL, including seven N417 variants (Figure S7). *SOCS1* mutations were present in 55.5% of PMBL patients, 30% of them harboring *SOCS1* inactivating mutations (Figure S5C). *TNFAIP3* mutations have also been frequently identified in PMBL (up to 36%)(38). We found *TNFAIP3* mutations to be significantly enriched in PMBL (61.1%, FDR=3.1x10⁻⁵), with all but one *TNFAIP3* mutated PMBL patient harboring truncating mutations (Figures 3 and S5C). The frequent *TNFAIP3* and *SOCS1* mutations in PMBL highlight the similarities between PMBL and cHL(38,39). Furthermore, no *MYD88*, *CD79B* or *CARD11* mutations were observed in PMBL patients (Figure 1), suggesting a PMBL dependence on *TNFAIP3* mutations for the constitutive activation of NFkB. Interestingly, significant *GNAI3* mutation enrichment was shown in PMBL rather than GCB in our cohort (50%, FDR=2.8x10⁻⁴) (Figures 3 and S5), and one third of *GNAI3* variants were potentially truncating mutations (Figure 4).

We discovered 46 *B2M* variants in 18.1% of total patients, significantly enriched in PMBL (50%, FDR=1.2x10⁻³) (Figures 1, 3 and S5C). Six of nine *B2M* mutated PMBL patients harbored truncating mutations and the remaining three presented pathogenic non-synonymous SNVs, two of which were a highly recurrent p.M1R variant predicted to affect the start codon (Figure 4). Recently, frequent *B2M* mutations leading to lack of protein expression were identified in cHL(9). Our similar findings in PMBL further highlight the molecular similarities between these two entities. *CD58* variants were also significantly enriched in PMBL (FDR=1.2x10⁻³) (Figures 3 and S5), with five of seven *CD58* mutated PMBL patients exhibiting truncating mutations, potentially leading to a lack of CD58 expression. Importantly, PD-1 blockade has recently shown promise as an effective treatment of relapsed or refractory cHL(40). Escape from T cell immunity via B2M and/or CD58 mutations could potentially affect the activity of PD-1 inhibitors in PMBL and cHL and warrants further investigation. Furthermore, we found 39 *CIITA* variants, enriched in PMBL as well (55.6% of PMBL versus 14.14% of total patients, FDR=3.1x10⁻⁵) (Figures 1, 3 and S5C). To our knowledge, this is the first study to identify truncating immunity pathway mutations as major in PMBL, although *CIITA/PDL1-2* translocations had been shown to impact PMBL survival(41).

ITPKB, *MFHAS1* and *XPO1* mutations were identified as significantly overrepresented in a relapsed/refractory DLBCL patient cohort(25), leading to their inclusion in the Lymphopanel. In our cohort, *ITPKB*, *MFHAS1* and *XPO1* mutations were all identified for the first time as being significantly enriched in PMBL patients ($FDR=1.4 \times 10^{-2}$, $FDR=3.9 \times 10^{-3}$ and $FDR=4.8 \times 10^{-10}$ respectively, Figure 3). The roles of *ITPKB* and *MFHAS1* in lymphomagenesis are not yet fully elucidated. *ITPKB* regulates B cell survival and function, and *ITPKB* deficiency leads to B cell antigen presentation unresponsiveness and decreased B cell survival, associated with specific overexpression of proapoptotic Bim protein(42). We found 48 *ITPKB* variants, present in 14% of total patients (Figures 1 and S5). *ITPKB* mutations were uniformly distributed along the protein sequence, excepting the seemingly conserved catalytic IPK domain, affected by only two non-synonymous SNVs (Figure 4). *MFHAS1* is a potential oncogene with highly conserved leucine-rich tandem repeats, isolated from a minimal common amplified region in malignant fibrous histiocytomas at 8p23.1. *MFHAS1* is also a target gene for chromosomal translocation t(8;14)(p23.1;q21) in B-cell lymphoma cell lines and has been shown to be tumorigenic in nude mice(43). In our cohort, *MFHAS1* variants were identified in 7.9% of total patients, and were distributed homogeneously along the coding sequence, with no recurrent mutations identified (Figure 4). Although the role of these potential oncogenes in lymphomagenesis is still unclear, their high mutation frequency in PMBL especially warrants further investigation. As for *XPO1*, it encodes CRM1, an exporter of several tumor suppressor proteins (TSPs). Cytoplasmic export of TSPs renders them inactive, indicating that *XPO1* acts as a proto-oncogene. *XPO1* mutations were present in 4.7% of total patients (1.2% of ABC, 1.2% of GCB, 3% of “other” and 38.9% of PMBL) (Figures 1 and S5). The mutation identified is recurrent, with all variants affecting E571 (Figure 4), as previously found in rare CLL cases (<5%)(44). Importantly, Selective Inhibitors of Nuclear Export (SINEs), have been shown to effectively target CRM1 and retain TSPs in the nucleus(45). Given the frequency of *XPO1* E571 mutations in PMBL, further investigation concerning their impact on response to SINEs is warranted (Jardin et al, under review).

Identification of gene mutations correlated with clinical characteristics and prognosis

We tested each gene in the Lymphopanel for correlation with clinical characteristics including age, stage, IPI, bone marrow involvement and presence of bulky disease.

CD79B, *KMT2D* and *MYD88* mutations were significantly correlated with age (Figure S8). For *CD79B* and *MYD88* mutations, enriched in ABC, this might be linked to the significantly

higher age of ABC patients ($p=1.01 \times 10^{-7}$ in our cohort)(46). As for *KMT2D* mutations, homogenous among subtypes, this result potentially suggests an accumulation of passenger-type mutations, particularly visible in this long gene (16.6 kb sequenced). *MYD88* mutations were also significantly correlated with higher IPI (FDR=0.04).

On the other hand, PMBL patients were significantly younger ($p=1.21 \times 10^{-8}$) and the large majority of genes whose mutations were significantly enriched in PMBL were also correlated with younger age (Figure S8). In addition, *B2M* and immunity pathway mutations were significantly inversely correlated with Ann Arbor stage (FDR= 3.2×10^{-3} and FDR=0.045 respectively), and *B2M* and *STAT6* mutations were significantly inversely correlated with IPI (FDR= 5.5×10^{-4} and FDR=0.026 respectively).

As expected, OS and PFS decreased with increasing IPI and ABC patients displayed significantly worse OS and PFS than GCB patients in the R-CHOP treatment group ($p=1.9 \times 10^{-2}$ and $p=6.6 \times 10^{-3}$ respectively) (Figure S9). Of note, PMBL patients in our cohort did not present the favorable prognosis typically associated with this subtype(47), perhaps due to the lack of dedicated treatment.

Prognostic impact was assessed for all Lymphopanel genes and subtypes, among patients treated with R-chemotherapy, separated into an R-CHOP group and an R-ACVBP group. Analyses over all subtypes were performed using multivariate Cox tests, while analyses of each subtype individually were performed using log-rank tests. In both cases, independent corrections of p-values were performed for OS and PFS. Gene mutations harboring prognostic impacts with uncorrected p-values < 0.05 are highlighted in Table 1 and Figure S10, and all survival analyses are presented in Table S7. We set an FDR threshold of 0.05 to detect gene mutations with significant prognostic impacts.

Among ABC DLBCL treated with R-CHOP, *TNFAIP3* mutations were significantly associated with lower OS (FDR= 7.86×10^{-4}) and PFS (FDR= 3.04×10^{-2}), while *GNAI3* mutations were significantly associated with lower PFS (FDR= 3.04×10^{-2}), (Figure 5). Of note, the poor prognostic impact of these mutations was not observed in patients treated with R-ACVBP, which, for *TNFAIP3* at least, might be linked to the improved survival observed in younger patients with DLBCL treated with R-ACVBP(48). These findings need to be confirmed in an independent cohort of patients, given the small sample size.

Unfortunately, the prognostic impact of *TNFAIP3* mutations in PMBL patients could not be assessed due to the existence of only one WT *TNFAIP3* PMBL patient treated with R-CHOP (Table S7). Moreover, previously described prognostic impacts of *TP53*, *FOXO1* or *MYD88*

mutations were not confirmed(35,49,50), although the impact of specific deleterious mutations was not analyzed on its own.

In conclusion, NGS is increasingly accessible in academic research settings, but its possibilities in routine clinical settings have yet to be thoroughly harnessed. This study has shown that, by using a restricted set of genes, not only can well-known mutations be tracked, but novel or rare mutations can also be identified and potentially targeted as well. Detailing subtype-enriched gene and pathway mutations is critical for optimal understanding and treatment of DLBCL: here, we have added to the field's current knowledge of the genetic heterogeneity between DLBCL subtypes, and identified novel clinical and prognostic correlations, which might also have an impact on therapeutic decisions. NGS with a consensus targeted panel could contribute valuable information to multidisciplinary meetings and constitute a molecular breakthrough in the way treatment decisions are made, by providing personalized mutational profiles of actionable targets. Furthermore, although this study was performed on frozen tumor samples, which are of limited availability, the Lymphopanel was designed to be effective in FFPE samples as well, further cementing its capacity to play an essential role in clinical disease management. In addition, our team has recently demonstrated that Lymphopanel NGS can be successfully performed using plasma-extracted cell-free circulating DNA, highlighting its feasibility and potential role in the monitoring of DLBCL(51). Taken together, these results serve as proof-of-principle that NGS with a consensus gene panel can alter the manner in which DLBCL patients are subclassified and treated.

Acknowledgements

This study was funded by grants from the Institut National du Cancer (INCA). We thank Marie-Hélène Delfau, Camille Laurent and Loïc Ysebaert for their critical review.

Contributors

SD, P-JV, SM, EB, PB, PR, J-PJ, MF, GS, HT, KL and FJ contributed to the conception and design of the study. TJM, FD, TF, CH, TL, CC-B, JB, TP, DC, BF, BC, RD, FP, AB, MA and NK collected clinical data. EB and CM performed NGS experiments. PP performed GEP experiments. SD, P-JV and SM performed statistical analyses and contributed to data interpretation. P-JV and SM developed the bioinformatics pipeline necessary for data

analysis. SD wrote the paper and all authors provided critical revisions and gave final approval to submit for publication.

Figure and Table Legends

Figure 1: Mutation frequencies in the total cohort and by subtype. Mutation frequencies in the total cohort are represented as a stacked bar chart. The number at the top of each bar represents the mutation frequency of the indicated gene in the total cohort. Bars are subdivided by DLBCL subtype, with segments proportional to mutation frequency. Potentially actionable targets are highlighted by indicating the appropriate class of molecule, which could potentially be used.

Figure 2: Mutation pathway heterogeneity among DLBCL subtypes. Pie-chart representations of mutation frequencies represented by pathway are represented for ABC (A), GCB (B), PMBL (C) and Other (D) subtypes. Mutation frequencies per gene and per subtype are shown here as the percentage of the total number of variants. Genes were grouped into 8 specific pathways: Immunity (*CIITA*, *B2M*, *TNFRSF14* and *CD58*), NOTCH (*NOTCH1* and *NOTCH2*), Apoptosis/Cell Cycle (*MFHAS1*, *XPO1*, *MYC*, *CDKN2A/B*, *FOXO1*, *TP53*, *GNA13* and *BCL2*), NFkB (*TNFAIP3*, *MYD88*, *PIM1*, *CARD11*, *IRF4* and *PRDM1*), Epigenetic Regulation (*EZH2*, *KMT2D*, *EP300*, *MEF2B* and *CREBBP*), MAP Kinases (*BRAF*), JAK-STAT (*SOCS1* and *STAT6*), and BCR (*CD79A/B*, *ITPKB*, *TCF3* and *ID3*).

Figure 3: Heatmap of mutation frequencies by subtype. Mutation frequencies in each subtype are indicated for each gene of the Lymphopanel. Mutation frequencies per gene and per subtype are shown here as the percentage of the total number of patients. Statistical significance of gene mutation enrichment in a given subtype is indicated by the FDR column. The horizontal line separates genes with FDR<0.05, considered significant, from genes with FDR≥0.05.

Figure 4. Mutations at the protein level. Protein representations were rendered using domains imported from the Pfam database (green). Exons were located using the CCDS database and were numbered automatically, not counting non-coding and spliced exons. Substitutions are depicted as diamonds, insertions as triangles and deletions as rectangles whose length varies according to the deletion size. A color code is also applied, with blue indicating non-synonymous substitutions or non-frameshift insertions, yellow indicating insertions and frameshift deletions, and pink indicating stop-gain and stop-loss mutations. Blue shading indicates sequenced regions.

Figure 5: *TNFAIP3* and *GNA13* mutations are linked to worse prognosis in R-CHOP-treated ABC patients. Survival analysis was performed on ABC patients treated with R-CHOP according to the presence or absence of *TNFAIP3* mutation (A, B) or *GNA13* mutation (C, D). Both *TNFAIP3* and *GNA13* mutations are associated with significantly less favorable prognosis in R-CHOP treated ABC patients.

Table 1. Prognostic impact of gene mutations among the Lymphopanel. Gene mutations with a tendency toward prognostic impact (uncorrected p<0.05) are indicated, for OS and/or PFS. The subtype and treatment cohort in which a prognostic impact was identified is shown, as is the number of mutant and WT patients for each survival analysis. HR column indicates Hazard Ratio. Bold type highlights significant FDR values.

- 498 1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO
 499 Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC;
 500 2008. 2008;
- 501 2. Alizadeh AAA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al.
 502 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
 503 Nature. 2000;403:503–11.
- 504 3. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-
 505 based method to diagnose clinically distinct subgroups of diffuse large B cell
 506 lymphoma. Proceedings of the National Academy of Sciences of the United States of
 507 America. 2003;100:9991–6.
- 508 4. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et
 509 al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a
 510 germinal center B-cell gene expression profile. Blood. 2002;99:2285–90.
- 511 5. Pfeifer M, Grau M, Lenze D, Wenzel S-S, Wolf A, Wollert-Wulf B, et al. PTEN loss
 512 defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-
 513 cell lymphoma. Proceedings of the National Academy of Sciences of the United States
 514 of America. 2013;110:12420–5.
- 515 6. Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave SS, Davis RE, et al. Molecular
 516 subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
 517 Proceedings of the National Academy of Sciences of the United States of America.
 518 2008;105:13520–5.
- 519 7. Lenz G, Staudt LM. Aggressive lymphomas. The New England journal of medicine.
 520 2010;362:1417–29.
- 521 8. Savage K, Monti S, Kutok J, Cattoretti G. The molecular signature of mediastinal large
 522 B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares
 523 features with classical Hodgkin. Blood. 2003;102:3871–80.
- 524 9. Reichel J, Chadburn A, Rubinstein PG, Giulino-roth L, Tam W, Liu Y, et al. Flow
 525 sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-
 526 Sternberg cells. Blood. 2015;125:1061–73.
- 527 10. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic
 528 significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a
 529 study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–
 530 8.
- 531 11. Mareschal S, Ruminy P, Bagacean C, Marchand V, Cornic M, Jais J-P, et al. Accurate
 532 Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-
 533 Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-
 534 Dependent Probe Amplification Assay: A CALYM Study. The Journal of molecular
 535 diagnostics : JMD. 2015;

- 536 12. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al.
 537 Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined
 538 by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
 539 Journal of clinical oncology : official journal of the American Society of Clinical
 540 Oncology. American Society of Clinical Oncology; 2015;33:2848–56.
- 541 13. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery
 542 and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by
 543 whole-exome sequencing. Proceedings of the National Academy of Sciences of the
 544 United States of America. 2012;109:3879–84.
- 545 14. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, et al. Mutational
 546 and structural analysis of diffuse large B-cell lymphoma using whole-genome
 547 sequencing. Blood. 2013;122:1256–65.
- 548 15. Mullighan CG. Genome sequencing of lymphoid malignancies. Blood. American
 549 Society of Hematology; 2013;122:3899–907.
- 550 16. Morin RD, Johnson N a, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic
 551 mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of
 552 germinal-center origin. Nature genetics. Nature Publishing Group; 2010;42:181–5.
- 553 17. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al.
 554 Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature.
 555 2011;476:298–303.
- 556 18. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, et al. Oncogenically
 557 active MYD88 mutations in human lymphoma. Nature. Nature Publishing Group;
 558 2011;470:115–9.
- 559 19. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of
 560 the coding genome of diffuse large B-cell lymphoma. Nature genetics. Nature
 561 Publishing Group; 2011;43:830–7.
- 562 20. Zhang J, Grubor V. Genetic heterogeneity of diffuse large B-cell lymphoma.
 563 Proceedings of the National Academy of Sciences. 2013;110:1398–403.
- 564 21. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-
 565 cell lymphoma. Blood. 2011;118:2659–69.
- 566 22. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais J-P, et al. Recurrent
 567 mutations of the STAT6 DNA binding domain in primary mediastinal B-cell
 568 lymphoma. Blood. 2009;114:1236–42.
- 569 23. Khodabakhshi A, Morin R, Fejes A. Recurrent targets of aberrant somatic
 570 hypermutation in lymphoma. Oncotarget. 2012;3:1308–19.
- 571 24. Bohers E, Mareschal S, Bertrand P, Viailly PJ, Dubois S, Maingonnat C, et al.
 572 Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next

- 573 generation sequencing and key elements in the precision medicine era. *Leukemia &*
574 *lymphoma*. 2014;1–10.
- 575 25. Mareschal S, Dubois S, Viailly P-J, Bertrand P, Bohers E, Maingonnat C, et al. Whole
576 exome sequencing of relapsed/refractory patients expands the repertoire of somatic
577 mutations in diffuse large B-cell lymphoma. *Genes, chromosomes & cancer*. 2015;
- 578 26. Dubois S, Mareschal S, Picquenot J-M, Viailly P-J, Bohers E, Cornic M, et al.
579 Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas:
580 Implications for targeted EZH2 inhibitor therapy? *Oncotarget*. 2015.
- 581 27. Foundation for Statistical Computing. R: A language and environment for statistical
582 computing. Vienna, Austria;
- 583 28. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B
584 cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nature*
585 *medicine*. Nature Publishing Group; 2015;21:922–6.
- 586 29. Zheng X, Ding N, Song Y, Feng L, Zhu J. Different sensitivity of germinal center B
587 cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. *Cancer cell*
588 *international*. 2014;14:32.
- 589 30. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, et al. Protein kinase C
590 inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-
591 cell lymphomas. *Cancer research*. 2011;71:2643–53.
- 592 31. Bohers E, Mareschal S, Bouzeflen A, Marchand V, Ruminy P, Maingonnat C, et al.
593 Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell
594 lymphoma. *Genes, chromosomes & cancer*. 2014;53:144–53.
- 595 32. Yang Y, Shaffer AL, Emre NCT, Ceribelli M, Zhang M, Wright G, et al. Exploiting
596 synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer cell*.
597 2012;21:723–37.
- 598 33. Brault L, Menter T, Obermann EC, Knapp S, Thommen S, Schwaller J, et al. PIM
599 kinases are progression markers and emerging therapeutic targets in diffuse large B-cell
600 lymphoma. *British journal of cancer*. Nature Publishing Group; 2012;107:491–500.
- 601 34. Schuetz JM, Johnson N a, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. BCL2
602 mutations in diffuse large B-cell lymphoma. *Leukemia*. Nature Publishing Group;
603 2012;26:1383–90.
- 604 35. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu W -m., et al. Mutational
605 profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients
606 treated with rituximab-CHOP: a report from an International DLBCL Rituximab-
607 CHOP Consortium Program study. *Blood*. 2012;120:3986–97.
- 608 36. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt
609 lymphoma pathogenesis and therapeutic targets from structural and functional
610 genomics. *Nature*. Nature Publishing Group; 2012;490:116–20.

37. Momose S, Weißbach S, Pischmarov J, Nedeva T, Bach E, Rudelius M, et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. *Leukemia*. 2015;
38. Schmitz R, Hansmann M-L, Bohle V, Martin-Subero JI, Hartmann S, Mechttersheimer G, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. *The Journal of experimental medicine*. 2009;206:981–9.
39. Weniger M a, Melzner I, Menz CK, Wegener S, Bucur a J, Dorsch K, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. *Oncogene*. 2006;25:2679–84.
40. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *New England Journal of Medicine*. 2014;372:141206100011003.
41. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature*. 2011;471:377–81.
42. Maréchal Y, Pesesse X, Jia Y, Pouillon V, Pérez-Morga D, Daniel J, et al. Inositol 1, 3, 4, 5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells. *Proceedings of the National Academy of Sciences*. 2007;104:13978–83.
43. Tagawa H, Karnan S, Kasugai Y, Tuzuki S, Suzuki R, Hosokawa Y, et al. MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8. *Oncogene*. 2004;23:2576–81.
44. Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. *Leukemia*. 2014;28:108–17.
45. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. *Blood*. 2012;120:4621–34.
46. Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. *Haematologica*. 2011;96:1888–90.
47. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *The New England journal of medicine*. 2013;368:1408–16.
48. Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. *Lancet (London, England)*. 2011;378:1858–67.

49. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJM, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. *Blood*. 2013;121:3666–74.
50. Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. *Leukemia*. Nature Publishing Group; 2014;28:2104–6.
51. Bohers E, Viailly P-J, Dubois S, Bertrand P, Maingonnat C, Mareschal S, et al. Somatic mutations of cell-free circulating DNA detected by Next Generation Sequencing reflect the genetic changes in both Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma tumors at the time of diagnosis. *Haematologica*. *Haematologica*; 2015;haematol.2015.123612.

Gene	Subtype	Cohort	Type	Mutant (n)	WT (n)	HR	p	FDR
<i>TNFAIP3</i>	ABC	R-CHOP	OS	6	48	9.04 [2.82-28.98]	9.03E-06	7.86E-04
<i>TNFAIP3</i>	ABC	R-CHOP	PFS	6	48	5.59 [1.91-16.39]	4.29E-04	3.04E-02
<i>GNA13</i>	ABC	R-CHOP	PFS	5	49	5.89 [1.86-18.64]	6.47E-04	3.04E-02
<i>B2M</i>	all	R-CHOP	PFS	16	100	0.12 [0.03-0.55]	6.24E-03	3.25E-01
<i>B2M</i>	all	R-CHOP	OS	16	100	0.11 [0.01-0.82]	3.13E-02	5.43E-01
<i>IRF4</i>	all	R-CHOP	OS	10	106	2.53 [1.10-5.87]	2.98E-02	5.43E-01
<i>CD79B</i>	all	R-CHOP	OS	19	97	0.31 [0.11-0.90]	3.13E-02	5.43E-01
<i>CD79B</i>	all	R-CHOP	PFS	19	97	0.29 [0.10-0.83]	2.15E-02	5.58E-01
<i>CD58</i>	all	R-CHOP	PFS	12	104	2.36 [1.07-5.20]	3.27E-02	5.67E-01
<i>GNA13</i>	ABC	R-CHOP	OS	5	49	3.68 [1.21-11.15]	1.36E-02	5.94E-01
<i>FOXO1</i>	GC	R-CHOP	OS	5	35	3.87 [1.00-15.07]	3.53E-02	7.72E-01
<i>CD79B</i>	ABC	R-CHOP	OS	16	38	0.35 [0.12-1.02]	4.44E-02	7.72E-01
<i>CD79B</i>	ABC	R-CHOP	PFS	16	38	0.33 [0.11-0.95]	3.07E-02	8.30E-01

Table 1. Prognostic impacts of gene mutations among the Lymphopanel

Figure 1




Fig. 2







Figure 3

	ABC n = 81	GCB n = 83	PMBL n = 18	other n = 33	FDR
STAT6	0%	14%	72%	6%	6.8e-14
XPO1	1%	1%	39%	3%	4.8e-10
SOCS1	6%	16%	56%	12%	2.5e-05
BCL2	1%	24%	0%	3%	2.5e-05
CIITA	12%	10%	56%	9%	3.1e-05
TNFAIP3	15%	11%	61%	15%	3.1e-05
CD79B	25%	2%	0%	3%	3.2e-05
PIM1	33%	8%	0%	6%	3.3e-05
GNA13	9%	12%	50%	12%	2.8e-04
CD58	6%	10%	39%	6%	1.2e-03
CREBBP	6%	31%	11%	24%	1.2e-03
B2M	9%	18%	50%	24%	1.2e-03
EZH2	0%	18%	6%	9%	1.8e-03
TNFRSF14	2%	17%	0%	24%	1.8e-03
MFHAS1	1%	10%	28%	9%	3.9e-03
MYD88	28%	10%	0%	15%	4.7e-03
ITPKB	9%	16%	39%	9%	1.4e-02
PRDM1	16%	6%	0%	3%	5.1e-02
NOTCH2	2%	10%	0%	15%	7.6e-02
IRF4	14%	5%	11%	0%	8.7e-02
MEF2B	12%	23%	11%	6%	1.4e-01
BRAF	0%	0%	0%	3%	2.1e-01
FOXO1	4%	12%	6%	3%	2.1e-01
KMT2D	41%	46%	17%	42%	2.2e-01
CARD11	14%	7%	0%	9%	3.5e-01
NOTCH1	7%	1%	6%	6%	3.7e-01
CD79A	0%	2%	0%	0%	4.5e-01
TP53	19%	16%	11%	6%	4.6e-01
CDKN2B	0%	1%	0%	3%	5.4e-01
ID3	5%	2%	6%	9%	5.5e-01
MYC	5%	10%	6%	3%	5.5e-01
CDKN2A	2%	1%	0%	0%	7.4e-01
TCF3	1%	2%	0%	0%	7.4e-01
EP300	15%	14%	17%	18%	9.6e-01




Figure 4




Figure 5

